Toll Free: 1-888-928-9744

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 84 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H1 2017, provides an overview of the Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) pipeline landscape.

Polyarticular juvenile idiopathic arthritis (PJIA) affects five or more joints. PJIA causes inflammation in small joints of the fingers and hands, but weight-bearing joints and the jaw can also be affected. Symptoms include fevers, pink rash, eye inflammation, joint pain, joint swelling and problems with bone development and growth. Treatment includes painkillers, NSAID and disease-modifying anti-rheumatic drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 2, 1, 2, 9, 2 and 1 respectively.

Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Overview Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Companies Involved in Therapeutics Development Biocon Ltd Coherus BioSciences Inc Livzon Pharmaceutical Group Inc Momenta Pharmaceuticals Inc Mycenax Biotech Inc Oncobiologics Inc Oncodesign SA Panacea Biotec Ltd Regeneron Pharmaceuticals Inc Sandoz International GmbH UCB SA Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Drug Profiles abatacept biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress adalimumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress adalimumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress adalimumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress adalimumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress adalimumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress adalimumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress adalimumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress adalimumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress certolizumab pegol - Drug Profile Product Description Mechanism Of Action R&D Progress etanercept biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress etanercept biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress etanercept biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress etanercept biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress etanercept biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress etanercept biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress sarilumab - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit RIP2 for Polyarthritis, Gastrointestinal Disorders and Rheumatoid Arthritis - Drug Profile Product Description Mechanism Of Action R&D Progress tocilizumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress tocilizumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress tocilizumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Dormant Projects Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Product Development Milestones Featured News & Press Releases Nov 02, 2016: Momenta and Mylan Initiate Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA (abatacept) Aug 30, 2016: FDA approves Erelzi, a biosimilar to Enbrel Jul 13, 2016: Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Polyarticular Juvenile Idiopathic Arthritis (PJIA), H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Biocon Ltd, H1 2017 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Coherus BioSciences Inc, H1 2017 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Livzon Pharmaceutical Group Inc, H1 2017 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Momenta Pharmaceuticals Inc, H1 2017 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Mycenax Biotech Inc, H1 2017 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Oncobiologics Inc, H1 2017 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Oncodesign SA, H1 2017 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Panacea Biotec Ltd, H1 2017 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Sandoz International GmbH, H1 2017 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by UCB SA, H1 2017 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Dormant Projects, H1 2017



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify